Elexacaftor / tezacaftor / ivacaftor with ivacaftor tablets or oral granules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Others

Brand
Trikafta
Company
Vertex Pharmaceuticals Incorporated
Medicine type
Chemical medicine
Therapeutic area
Respiratory & allergy
Indications recorded in the public source
US: Cystic fibrosis in patients aged 2 years or older with a clinical diagnosis and at least one CFTR variant that is responsive on clinical/in-vitro evidence or produces CFTR protein. The product co-packages the triple combination with separate ivacaftor. Genotype confirmation is required when unknown.
Indication source and scope
US prescribing information revised March 2026. Selected overseas indications; does not establish the Chinese approved scope.
Prescribing-information limitations
Overseas official prescribing information linked; a complete current Chinese label has not been verified.
China availability status
Chinese approval, locally approved indications and current availability have not been independently verified in this import.
Overseas status
See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
Insurance classification
Not yet verified
Insurance edition
Chinese national insurance review pending
Insurance verification notes
No reimbursement determination was made for this addition; missing information is not proof of exclusion.

Sources

Evidence reviewed:

Open the interactive record, public price references and discussions